We have devised a safer strategy to target these tumors as we found that BCL-XL/MCL-1 co-dependent SCLC cells can be synergistically killed with a combination of DT2216 (a selective BCL-XL PROTAC degrader) and AZD8055 (an mTOR inhibitor). Here, BCL2L1 is linked to small cell lung carcinoma.